Born in Milan in 1955, Sergio Dompé is an entrepreneur in the pharmaceutical and biotechnological industries and President of Dompé, a pharmaceutical group developing innovative therapeutic solutions for rare and orphan diseases. He has been awarded honorary doctorates in Biotechnology with specialization in pharmaceutics (Bologna, 1996), Medical Biotechnology (L’Aquila, 2005) and Pharmacy (Urbino, 2010). Among the first in Italy to grasp the true value of biotechnology applied to human health, he has developed an extensive network of partnerships with the most significant research centres for diseases in Dompé’s main therapeutic fields. In 2016, he funded and established Movendo, an innovative medical company sparkled by an idea by the Italian Institute of Technology: to develop the most advanced technologies at the service of mankind and products in the field of physical movement rehabilitation. In 2004 he was awarded the “La Lombardia per il lavoro” prize, in recognition of his value as one of Lombardy’s most innovative entrepreneurs.

In 2016, he received the Prize of the Foundation Aiuto per la Ricerca sulle Malattie Rare (A.R.M.R.), regularly awarded to those who distinguish themselves in the research field.

In 2017 he was awarded the Guido Carli prize.

Institutional offices held

• From 1998 to 2004: President of Assobiotec

• Since 2004, anchor investor in Philogen, a leader in the research and development of antibodies

• From 2005 to 2011: President of Farmindustria

• From 2006 to 2011: Chairman of the Evaluation Committee of the CNR (Consiglio Nazionale delle Ricerche, National Research Council).

• From 2007 to 2015: member of the Board of the IIT (Italian Institute of Technology) Foundation

• From 2014 to 2016: member of the Patent Experts Committee of the CNR

• From 2014 to 2016: member of the Board of Regency of the Bank of Italy (Milan office)

• Since 2015: member of the General Council of Confindustria as representative of Farmindustria

• Since 2016: Censor of the Bank of Italy (Milan office)

• Since 2019: Vice President of Assolombarda with delegated powers over Life Sciences

• 2020: Chairman of the 2021 B20 Life Sciences task-force.

• Since November 2023: President of the Leonardo Committee

Nathalie Dompé is Co-CEO of Dompé farmaceutici. Nathalie is responsible for the oversight, market development, and strategic approval of all new drugs launched by Dompé in the United States. She explores new opportunities for the company through interactions with other business leaders in the pharmaceutical and high tech industries.

Nathalie is concurrently CEO, of Dompé Holdings, a diversified holding company in Europe with business interests in pharmaceuticals, agriculture, and hi-tech. She sits on the board of several companies including Movendo, Philogen and Dompé farmaceutici. Nathalie graduated with Honors in Business Administration from Bocconi University in Milan. In her free time Nathalie enjoys spending time with her family in the Bay Area, and abroad.

After graduating in Economics at "La Sapienza" University in Rome, she completed her studies with an MBA at Politecnico di Milano.

In 2005 she joined Bain & Company where she gained a consolidated and internationally recognized expertise in the healthcare sector.

She joined Dompé in 2018 as Chief Operating Officer (COO) and she’s in charge of leading the company's internationalization project, with an emphasis on biotechnology, following the FDA approval of the first therapy for neurotrophic keratitis.

The COO coordinates the company’s activities, with the strategic goal of providing patients with highly innovative solutions in response to unmet medical needs.

A highly accomplished senior executive in the pharmaceutical industry with over 25 years of experience, Sullivan excels in strategic planning, operational efficiency, product launches in the rare disease space, and P&L management.

Her impressive track record, from Pfizer to Amgen, demonstrates her leadership acumen, making her a valuable asset of our organization. During her tenure at Amgen, she played a pivotal role in integrating strategic acquisitions and has been Vice President & Managing Director for Amgen, Australia & New Zealand.

Sullivan earned a Bachelor of Science in Biotechnology from the University of North Florida and completed post-baccalaureate work at Duquesne University with a concentration in chemistry.

With a degree in Medical Chemistry from The Sapienza University of Rome, Marcello is a member of the American Chemical Society since 1988 and the Italian Chemistry Society since 2006.

After a brief period as a university researcher, he joined Dompé as a team leader, followed by a period as Research Director and, since 2009, as a Chief Scientific Officer.

He leads Dompe’s Research and Development activities and pre-clinical and clinical drug development programs - from active ingredient identification to market authorization - including relationships with international regulatory authorities.

Marcello also holds a number of university teaching positions and maintains his scientific interests, with published work in over forty scientific journals. He is Associate Editor for several journals.

He has also filed over thirty international patents.

With a robust background in clinical research and a deep expertise in drug development, Ahmed's career spans several high-profile roles across leading pharmaceutical & biotechnology companies such as Amgen, Biogen and Alexion. Ahmed earned his medical degree from the University of Cairo and completed his Ph.D. in Pharmacology and Toxicology at the University of Connecticut. His early career included significant contributions, where he led efforts in personalized medicine and championed precision medicine initiatives leveraging earlier AI platforms. Later in his career, he led and oversaw multiple successful clinical programs that brought novel therapies to patients with high unmet medical need indications. In his role prior to joining Dompe, he led the development organization at BlueRock Therapeutics and drove the company’s mission to harness the power of cell therapy, navigating through mostly uncharted territories. Ahmed’s leadership is characterized by his strategic vision and commitment to advancing medical science through innovative research and development. His work at previous roles reflect a dedication to improving patient lives and pushing the boundaries of what is possible in medical research and therapeutics.

Marc is a highly accomplished executive in the pharmaceutical industry, bringing extensive experience across all phases of drug development, multiple therapeutic areas, and various drug modalities. With nearly two decades in drug development, Marc has successfully led or overseen global regulatory submissions, health authority meetings, and obtained marketing application approvals in all major markets.  

Marc spent 15 years at Amgen holding various leadership positions in Regulatory Affairs and Program Leadership. Following Amgen, Marc joined a startup biotechnology company as employee number eight heading Regulatory Affairs and Program Leadership where he built high performing teams supporting multiple acquisitions and an initial public offering. Exposure to both large and startup biotechnology companies has provided Marc with a unique and valuable combination of skills and experiences. Those experiences include rare diseases, large outcomes studies, combination products, and multiple Advisory Committee Meetings with the FDA. Marc’s passion for developing innovative and impactful treatments to meet the unmet needs of patients made him a welcomed addition to Dompe.

Marc holds both an MS in Physiological Science and a PhD in Molecular, Cellular, and Integrative Physiology from the University of California, Los Angeles. In his free time, he enjoys staying active, traveling, and spending time with his family and friends.

Graduated in Medicine and Surgery summa cum laude, Flavio completed his specialization program in ophthalmology and a Ph.D. at the Campus Bio-Medico University of Rome. He also completed a postdoctoral fellowship in ocular surface glycobiology at the Schepens Eye Research Institute - Harvard Medical School in Boston.

Prior to joining Dompé, Flavio researched the application of neurotrophins in ophthalmic and neurodegenerative diseases and was an adjunct associate professor of biology at Temple University in Philadelphia.

His professional experience includes positions at the IRCCS G.B. Bietti Hospital in Rome as a clinical scientist and as a consultant ophthalmologist at the Campus Biomedico University of Rome and the Cornea and Ocular Surface Unit of the Vita-Salute San Raffaele University of Milan.

Flavio joined Dompé in 2014, and has been instrumental in developing Oxervate into a revolutionary product for a rare and potentially blinding orphan corneal disease, neurotrophic keratitis. In 2019 he was appointed Chief Medical Officer.

As Chief Medical Officer and Head of R&D for the Ophthalmology and Neurotrophin platforms, Flavio leads all clinical research and development programs in ophthalmology with particular attention to the applications of NGF in ophthalmic diseases and other therapeutic areas.

He is the author of numerous scientific publications in international journals.

Davide graduated in Business Administration from Bocconi University in Milan. Since 2015, he has been managing Dompé’s Commercial Operations in Primary Care at national and international level.

Before taking on this role, he held a number of different marketing and sales positions within the company, focusing on the promotion and development of OTC and ethical drugs.

Gianluca is Director of Strategic Planning and Business Development at Dompé farmaceutici. He joined Engitix’s Board of Directors in January 2022, following the closing of the collaboration and investment agreement with Dompé farmaceutici.
Gianluca has almost 10 years of experience in management consulting, with a specific focus in the Life Sciences. He has led strategic projects with several Fortune 500 companies that ranged from biopharmaceutical to medical devices and diagnostics.
He holds a Master Degree in Business Administration from the Università di Pavia, Italy

Graduated in Biological Science at La Sapienza University in Rome, after a brief period as researcher, Stefano started his career in the pharmaceutical and consumer health business, working for both national and multinational companies, across multiple sites and geographical regions. Coming from Alfasigma, where, as Corporate Quality and Operations, he has played a key role in the post-merger integration process.

He also worked for Catalent Pharma solutions, a leading provider in the CDMO business, firstly as VP Quality Europe, Japan and Australia and later assuming the role of General Manager of the Italian subsidiary. Stefano joined Dompé in 2020 as Head of Quality Corporate VP, being accountable for strengthening quality governance model and continuously improving company quality standards.

From 2021 as Chief Industrial Officer, he is in charge of leading the industrial team, supporting the company’s strategic growth, while improving overall manufacturing network efficiency.

Daniele holds a degree in Business Administration from Bocconi University in Milan. He has worked for over 30 years in the ICT transformation and digitization of various companies and industries.

He began his professional career as a consultant in a leading consulting firm, then as a project and IT manager in a regional group of supermarkets.

He joined Autogrill in 1999 as ICT project manager responsible for the European branches, and then held the role of CIO for Italy and Europe for over 10 years, carrying out various and recognized digital innovation projects.

He contributed to the creation of the ICT & Admin shared service center and its transformation into a separate legal entity (AABS spa) which he led as General Manager until 2019.

Together with G. Bongiorno and G. Vaia he has published the book “CIOs and the digital transformation. A new leadership role "(Springer 2018)

Giuseppe Andreano joined Dompé in 2007.

Following a degree in Business Administration from Bocconi University in Milan, Giuseppe gained experience in administration and financial management with major multinational companies.

Giuseppe is Dompe’s Chief Financial Officer in charge of administration, budgets and financial control. He also manages IT and purchases.

Andrea has over 20 years of experience in the Human Resources, Legal & Compliance Departments of commercial and industrial organizations in the pharma sector. Graduated in Law from the Università Statale di Milano and from Insead Business School’s Leadership Development Program, he is a lawyer articled clerk and has worked extensively in multinational pharmaceutical groups with an excellent track record ranging from HR to compliance.

Paul Curtin has extensive global corporate leadership experience across a broad range of legal areas: compliance, regulatory, privacy, and US Department of Justice investigations/settlements, including significant ex-US exposure with anti-corruption and anti-money-laundering work within the biotech and pharmaceutical industries. He has developed and managed five corporate compliance and privacy programs and spearheaded compliance and privacy matters in 75 countries within North America, EMEA, LATAM, and Asia-Pacific.

Most recently, as Global Chief Compliance Officer & Chief Privacy Officer at Intercept Pharmaceuticals, Paul directed global legislative and regulatory developments that impacted drug research, development, and commercialization, including GDPR, FCPA, AML, Customs & Trade, and Antitrust. Prior to joining Intercept, he was Compliance Officer, International Markets & Research, Development & Manufacturing at Allergan plc.

Previously, Paul held senior compliance positions at Clinical Data Inc., Acorda Therapeutics Inc., Applied Biosystems Inc., and Purdue Pharma L.P. Early in his career, he was a corporate, healthcare, and regulatory attorney with Wiggin and Dana.  

Paul holds a JD from the Albany Law School of Union University in Albany, NY, and a BA in English Literature and Irish Politics & Literature from Boston College in Chestnut Hill, MA. He is certified as a European Healthcare Compliance Professional, a Compliance and Ethics Professional (CCEP), and a Healthcare Compliance Professional. He has been admitted to the bar in Connecticut and New York, the United States Federal Court, District of Connecticut, Southern and Eastern Districts of New York, and the United States Court of Appeals for the Second Circuit.

Sheila joined Dompé in 2020. In her role she is accountable for the commitment to and further strengthening of the US Compliance Program through continuous improvement of policies, procedures, and applicab!e standards set forth by the Office of lnspector General. Sheila comes to Dompé with a wealth of experience and knowledge within the US health-care compliance and legal arena.

Prior to joming Dompé, Sheila held several positions in health-care compliance, including associate general counsel at Abigall Hearthcare lnc. and the compliance business partner for the lnflammation, Oncology, and Nephrology businesses and Value. Access & Government Pricing function at Amgen. lnc. She was also instrumental in the task force that established a robust health-care compliance function at Onyx Pharmaceuticals, lnc. This endeavor translated into building out the seven pillars of a strong compliance program as set and required by the US Office of lnspector General.

Sheila has always been passionate about contributing to humanitarian efforts on both a local and a global scale. She volunteers at her local church and several intenational agencies to assist with the needs of communnities that are often set aside by the norms of society. She loves music and is a professional dancer and avid kickboxer.

Marco joined Dompé in 2024. In his role he is accountable for further strengthening the EU Compliance Program and to support Headquarter functions through continuous improvement of the program elements, notably risk management, controls and policies while ensuring smooth and agile processes execution.

Marco comes to Dompé with a comprehensive experience and knowledge within the EMEA health-care compliance environment with experiences in R&D and Manufacturing.

Prior to joining Dompé, Marco held several positions in both medical and marketing, focusing in health-care compliance since 2005.

He had a long tenure in Genzyme followed by AstraZeneca, Teva and more recently Biogen, where he covered different roles with a steady increase in responsibilities and remit. He was leading different programs, amongst them Global Compliance support to Social Media and Digital Healthcare initiatives. Marco is a great believer in teamwork and well being in the workplace. He has been part of DE&I working groups in previous Companies and he is a voluntary indoor volleyball referee in a local sport association. He loves spending time with family and friends, and he is passionate about skiing and indoor volleyball.

Guido Romeo holds a degree in Agricultural Economics from the University of Bologna in Italy and a double Master's in Journalism and Science Communication from the École Supérieure de Journalisme and the University of Lille in France. With experience in journalism, corporate communications, and public affairs, Guido manages public narratives and corporate reputations globally at Dompé. His work focuses on healthcare innovation and public policy, aligning with Dompé's efforts in medical research and therapies.